S
Sanjeev Saksena
Researcher at Atlantic Health System
Publications - 174
Citations - 6606
Sanjeev Saksena is an academic researcher from Atlantic Health System. The author has contributed to research in topics: Atrial fibrillation & Cardioversion. The author has an hindex of 44, co-authored 169 publications receiving 6463 citations. Previous affiliations of Sanjeev Saksena include University of Minnesota & Newark Beth Israel Medical Center.
Papers
More filters
Journal ArticleDOI
Management of the patient with an implantable cardioverter-defibrillator in the third millennium.
Sanjeev Saksena,Nandini Madan +1 more
TL;DR: Optimal patient management requires intimate knowledge of these complex devices and of the diverse arrhythmias that may be treatable by a single multifaceted ICD device.
Journal ArticleDOI
Management of atrial fibrillation: two decades of progress — a scientific statement from the European Cardiac Arrhythmia Society
Samuel Lévy,Gerhard Steinbeck,Luca Santini,Michael Nabauer,Diego Penela Maceda,Bharat K. Kantharia,Sanjeev Saksena,Riccardo Cappato +7 more
TL;DR: Significant progress has been made within the past 2 decades both in the pharmacological and non-pharmacological managements of this cardiac arrhythmia.
Book
Electrical therapy for cardiac arrhythmias : pacing, antitachycardia devices, catheter ablation
TL;DR: A comprehensive presentation of electrical therapy by more than 40 highly respected authorities, including complete coverage of tachycardia (fast rate) therapy, as well as bradycardias (conventional cardiac pacing).
Journal ArticleDOI
Implantable defibrillators in the third millennium: increasingly relegated to a standby role?
TL;DR: In the last five years, evidence has accumulated confirming the superiority of implantable cardioverter-defibrillator (ICD) therapy compared to antiarrhythmic drug therapy for prevention of sudden death as discussed by the authors.
Journal ArticleDOI
The Role of Multisite Atrial Pacing in Rhythm Control in AF: Insights from Sub-analyses of the Dual Site Atrial Pacing for Prevention of Atrial Fibrillation Study
TL;DR: DAY is an important therapeutic tool in an “hybrid” strategy for management of drug-refractory AF and can facilitate efficacy of other antiarrhythmic therapies in AF.